Announced
Financials
Sources
Tags
Friendly
Medical Equipment
Single Bidder
Pending
diagnostics
Majority
United Kingdom
Acquisition
Cross Border
Private
Synopsis
Biosynex, a biopharmaceutical company, agreed to acquire a 75% stake in BHR Pharmaceuticals, a provider of Point Of Care diagnostics. Financial terms were not disclosed. "We are very pleased with this acquisition alongside of the founders in BHR, which symbolizes the first majority strategic acquisition in the international development of BIOSYNEX in a major market in which the Point of Care segment is already well established developed. This stake represents a first step in the acquisition strategy pursued actively by Biosynex on 3 axes: complete its product offer, acquire technologies and access international distribution networks," Larry Abensur, Biosynex CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.